MedPath

AnteoTech Ltd

🇦🇺Australia
Ownership
-
Employees
40
Market Cap
-
Website
Introduction

AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP.

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)

Terminated
Conditions
SARS-CoV-2 Infection
First Posted Date
2022-11-16
Last Posted Date
2024-12-06
Lead Sponsor
AnteoTech Ltd
Target Recruit Count
599
Registration Number
NCT05618561
Locations
🇭🇷

Institut Virion, Split, Croatia

🇬🇷

Laiko General Hospital, Athens, Greece

🇪🇸

Centro de Salud Fuentes Norte, Zaragoza, Aragón, Spain

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.